News > Latest News

Walk News | Sponsor & Foundation News | News in the Parkinson's Disease Community

Johns Hopkins Startup Neuraly Plans Phase 1 Parkinson’s Trial


(July 23, 2018) - A new startup from Johns Hopkins has launched with $36 million in financing in the pursuit of disease-modifying agents for Parkinson’s disease and other neurodegenerative disorders. The company’s pipeline is built around NLY01, a long-acting glucagon-like peptide-1 receptor agonist that penetrates the brain and has shown promise as a neuroprotective agent. Read more